Curated News
By: NewsRamp Editorial Staff
August 09, 2024
Clene Inc. Featured in BioMedWire Podcast for Novel Approach to Neurodegenerative Disease Treatment
Discuss on Reddit
Discuss on SubstackTLDR
- Clene (NASDAQ: CLNN) is pioneering a unique approach to treating neurodegenerative diseases, potentially giving them a competitive advantage in the market.
- Clene CEO Rob Etherington discusses the use of an oral suspension to improve mitochondrial health and protect neuron function in the treatment of diseases such as ALS and MS.
- Clene's novel approach to treating neurodegenerative diseases could potentially improve the quality of life for patients and increase survival rates, making tomorrow better than today.
- The use of an oral suspension to treat neurodegenerative diseases is an interesting and innovative approach that could revolutionize the way these diseases are treated.
Impact - Why it Matters
This news matters because it highlights Clene's innovative approach to treating neurodegenerative diseases, offering hope for those affected by conditions like ALS and MS. The company's focus on improving mitochondrial health and protecting neuronal function could potentially lead to groundbreaking advancements in the field of biopharmaceuticals, impacting the lives of patients and their families.
Summary
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, was featured in the latest episode of the BioMedWire Podcast, where CEO Rob Etherington discussed the company’s mission to treat neurodegenerative diseases such as ALS and MS. Clene is focused on improving mitochondrial health and protecting neuronal function, pioneering a unique oral suspension drug to address deficits in patients. The company’s investigational therapy, CNM-Au8, aims to improve the survival and function of central nervous system cells while reducing oxidative stress.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene Inc. Featured in BioMedWire Podcast for Novel Approach to Neurodegenerative Disease Treatment
